ArticleEndocrine2012
Association between E-cadherin (CDH1) polymorphisms and papillary thyroid carcinoma risk in Han Chinese population.
Article in Endocrine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.PloS one · 2012Pooled it
- The impact of the genetic background in a patient with papillary thyroid cancer and familial adenomatous polyposis.Archives of endocrinology and metabolism · 2022Article
- Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis?SpringerPlus · 2016Article
- Association between E-cadherin (CDH1) polymorphisms and pancreatic cancer risk in Han Chinese population.International journal of clinical and experimental pathology · 2015Article
- Correlation between SNPs in CDH1 and gastric cancer in Chinese population.Open medicine (Warsaw, Poland) · 2015Article
- BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.Endocrine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the associations between E-cadherin gene (CDH1) polymorphisms and papillary thyroid carcinoma (PTC) risk predisposition. We undertook a case-control study to analyze three CDH1 polymorphisms (+54T>C, -160C>A, and -347G→GA) in an Han Chinese population, by extraction of genomic DNA from the peripheral blood of 98 patients with PTC and 176 control participants, and performed CDH1 genotyping using DNA sequencing. The obtained results indicated that overall, no statistically significant association was observed in +54T>C. Nevertheless, -347G→GA genotype was at increased risk of PTC (P = 0.001; odds ratio (OR) = 2.12, CI 95%:1.24-3.34). Furthermore, -347GA/GA genotype thyroid cancers were more significantly common in patients with tumor size of ≥20 mm than G or G/GA genotypes PTC and in cases of advanced T stage. However, -160C>A genotype demonstrated a protective effect in PTCs (P = 0.006; OR = 0.59, CI 95%: 0.42-0.87). These findings led us to conclude that polymorphism in -347G→GA was observed to be associated with susceptibility of PTC. However, -160C>A polymorphism indicated to play a protective role in susceptibility to PTC. Nevertheless, further investigation with a larger sample size is needed to support our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.